Can-Fite BioPharma Ltd. announced its 2026 Annual General Meeting of Shareholders on May 28, 2026, proposing director re-election, authorized share capital increase from 14M to 30M shares, executive option grants, and auditor re-appointment.
Key takeaways
Annual General Meeting scheduled for May 28, 2026 at 3:00 p.m. Israel time in Ramat Gan.
Record date is May 4, 2026 for shareholders and ADS holders.
Proposal to re-elect Abraham Sartani as Class I director for three-year term.
Proposal to increase authorized ordinary shares from 14,000,000 to 30,000,000.
Proposals to grant options to Chairman Dr. Pnina Fishman and CEO/CFO Mr. Motti Farbstein.
Re-appointment of Kost Forer Gabbay & Kasierer (EY) as independent auditors for 2026.
4,285,093 ordinary shares outstanding as of April 22, 2026.